|Bid||34.00 x 13100|
|Ask||34.01 x 3300|
|Day's Range||33.84 - 34.06|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.64|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
Pfizer was trading at a forward PE multiple of ~12.8x on June 22, 2017, compared to the industry average of ~16.6x.
Merck announced this morning that anacetrapib, a cholesterol-lowering medicine, reduced heart problems and strokes in a 30,000-patient clinical trial, giving the drug giant a success where Pfizer, Eli Lilly and Roche have all failed.